Pfizer’s Covid-19 Vaccine Generated 10 Times More Antibodies Than China’s Sinovac Shot, Hong Kong Study Shows

People who were inoculated with the Pfizer-BioNTech Covid-19 vaccine had ten times the amount of antibodies compared to those who had received the Chinese-developed Sinovac vaccine, a Hong Kong study has shown, likely offering evidence about the varying levels of protection offered by different Covid jabs.

According to the study published in The Lancet, the difference in concentrations of neutralizing antibodies “could translate into substantial differences in vaccine effectiveness.”

The study was based on samples collected from 1,442 healthcare workers working in medical clinics, public and private hospitals in Hong Kong.

The recipients of the Sinovac had “similar or lower” levels of antibodies compared to patients who had been infected by Covid-19 and had managed to fight off the disease, AFP reported.

The study only looked at concentrations of neutralizing antibodies—which are not the only measure of a vaccine’s effectiveness—and did not include any data on T cells and other potential markers of protection. 

Leave a Comment